Recent advances in the management of osteoporosis

F1000Research
Seiji Fukumoto, Toshio Matsumoto

Abstract

There has been substantial progress in the management of patients with osteoporosis and the prevention of osteoporotic fractures. Currently available strong anti-resorptive agents are bisphosphonates and an anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody, denosumab. Although bisphosphonates and denosumab both inhibit bone resorption and prevent vertebral and non-vertebral fractures, their mechanisms of action are different. Whereas bisphosphonates' effects on bone mineral density and fracture peak around 3 to 5 years and become plateaued, those of denosumab are maintained for up to 10 years. There are differences in the modes of action of these two drugs. Bisphosphonates accumulate on the mineralized bone surface and are released by the acid environment under osteoclastic bone resorption, whereas denosumab is not accumulated on bone but directly binds RANKL and inhibits its binding to the receptor RANK. Thus, the reduction in denosumab concentration 4 to 6 months after injection may enable RANK to bind to RANKL, where it is highly expressed, such as in damaged bone regions. As anabolic agents, only teriparatide has been available for a long time, but abaloparatide, a synthetic analog of PTHrP(1-34), is...Continue Reading

References

Sep 23, 2003·The New England Journal of Medicine·Joel S FinkelsteinRobert M Neer
Mar 19, 2004·The New England Journal of Medicine·Henry G BoneUNKNOWN Alendronate Phase III Osteoporosis Treatment Study Group
Dec 28, 2006·JAMA : the Journal of the American Medical Association·Dennis M BlackUNKNOWN FLEX Research Group
Aug 13, 2009·The New England Journal of Medicine·Steven R CummingsUNKNOWN FREEDOM Trial
Nov 12, 2009·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·M A LawsonR G G Russell
Feb 19, 2010·The Journal of Clinical Endocrinology and Metabolism·Joel S FinkelsteinRobert M Neer
Sep 4, 2010·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Felicia CosmanSteven Boonen
Nov 30, 2010·Current Medicinal Chemistry·K OhnoM Takeuchi
Nov 19, 2011·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Matthew AustinUNKNOWN FREEDOM Trial
Apr 24, 2012·The Journal of Clinical Endocrinology and Metabolism·Sundeep KhoslaJohn T Potts
Feb 8, 2013·Nature Medicine·Roland Baron, Michaela Kneissel
Feb 12, 2014·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·T-C LinS-J Lin
Jul 22, 2014·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Joy N TsaiBenjamin Z Leder
Jul 31, 2014·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M A PaggiosiR Eastell
Dec 30, 2014·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Dennis M BlackRichard Eastell
Jul 24, 2015·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·S PapapoulosH G Bone
Sep 10, 2015·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Robert A AdlerDeborah E Sellmeyer
Dec 24, 2015·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·A W PoppK Lippuner
Mar 12, 2016·The Journal of Clinical Endocrinology and Metabolism·J N TsaiB Z Leder
Jun 24, 2016·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Sundeep Khosla, Elizabeth Shane
Aug 18, 2016·JAMA : the Journal of the American Medical Association·Paul D MillerUNKNOWN ACTIVE Study Investigators
Nov 1, 2016·The New England Journal of Medicine·Felicia CosmanAndreas Grauer

❮ Previous
Next ❯

Citations

Mar 25, 2020·Medicina·Vasileios Alexandros KarakousisTheodora Papamitsou
Apr 24, 2020·International Journal of Molecular Medicine·Yan SunWen-Hui Lee
Sep 18, 2020·Journal of Bone and Mineral Metabolism·Jing-Yi XueLong Guo
Nov 23, 2017·Frontiers in Pharmacology·Vito PavoneGiuseppe Sessa
Jan 26, 2018·International Journal of Molecular Sciences·Lifang HuAirong Qian
Nov 9, 2019·International Journal of Molecular Sciences·Kazuhiro MaedaKeishi Marumo
Feb 13, 2020·Inflammation and Regeneration·Takehito OnoTomoki Nakashima
Sep 24, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Yongming ShuaiFanhui Zeng
Aug 23, 2018·Bone Research·M Noelle KnightKurt D Hankenson
Feb 27, 2018·Journal of Clinical Periodontology·Márcio Diniz-FreitasJacobo Limeres

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nihon rinsho. Japanese journal of clinical medicine
Toshio Matsumoto
Therapeutic Advances in Musculoskeletal Disease
Anne Sophie Koldkjær SøllingBente L Langdahl
British Journal of Clinical Pharmacology
Gaia Tabacco, John P Bilezikian
© 2022 Meta ULC. All rights reserved